Emcure Pharma shares rise to the 10% upper circuit and touch a 52-week high after the company reports stronger earnings for the September quarter. Business Line reports a 29.31% increase in consolidated net profit to ₹325.06 crore, while NDTV highlights higher profitability and growth figures around the same results.
Several outlets connect the share move to forward-looking signals. Economic Times says Emcure lifts full-year growth guidance after its Q2 performance, with broker Jefferies raising its target price by 8%, and notes expectations around international business, domestic improvement, and the product pipeline. NDTV also frames the results around double-digit revenue growth and operating profit, with a separate report citing international business growth of 34.5% year-on-year.
Across coverage, the common thread is the link between the reported quarterly numbers—especially profit and international performance—and positive market reaction, including updated guidance and broker views.
